RU2004119963A - Ингибиторы вич интегразы - Google Patents
Ингибиторы вич интегразы Download PDFInfo
- Publication number
- RU2004119963A RU2004119963A RU2004119963/04A RU2004119963A RU2004119963A RU 2004119963 A RU2004119963 A RU 2004119963A RU 2004119963/04 A RU2004119963/04 A RU 2004119963/04A RU 2004119963 A RU2004119963 A RU 2004119963A RU 2004119963 A RU2004119963 A RU 2004119963A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- pharmaceutically acceptable
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- -1 3 - [(3-Cyano-4-fluorobenzyl) methoxycarbamoyl] -2-hydroxyacrylic acid Chemical compound 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- GACIOSIZKMLELV-POHAHGRESA-N (z)-4-[(4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(/O)=C/C(=O)N(OC)CC1=CC=C(F)C=C1 GACIOSIZKMLELV-POHAHGRESA-N 0.000 claims 1
- UBJXQYGGGBFPFU-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluoro-3-methylphenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(C)=C1 UBJXQYGGGBFPFU-UHFFFAOYSA-N 0.000 claims 1
- JLUPGSPHOGFEOB-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C=C1 JLUPGSPHOGFEOB-UHFFFAOYSA-N 0.000 claims 1
- YDEQMOHWDHVKTH-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-ethoxy-n-[(4-fluorophenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC)CC1=CC=C(F)C=C1 YDEQMOHWDHVKTH-UHFFFAOYSA-N 0.000 claims 1
- VVTORXJRSZVVLL-UHFFFAOYSA-N 4-[ethoxy-[(4-fluorophenyl)methyl]amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OCC)CC1=CC=C(F)C=C1 VVTORXJRSZVVLL-UHFFFAOYSA-N 0.000 claims 1
- AIIAOLREXSFWSX-UHFFFAOYSA-N C1=CC(=C(C=C1CCONC(=O)C=C(C(=O)O)O)Br)F Chemical compound C1=CC(=C(C=C1CCONC(=O)C=C(C(=O)O)O)Br)F AIIAOLREXSFWSX-UHFFFAOYSA-N 0.000 claims 1
- OKBWUIDLFUHFCW-UHFFFAOYSA-N C1=CC(=C(C=C1CCONC(=O)C=C(C(=O)O)O)F)F Chemical compound C1=CC(=C(C=C1CCONC(=O)C=C(C(=O)O)O)F)F OKBWUIDLFUHFCW-UHFFFAOYSA-N 0.000 claims 1
- SYOUNFPGFYUNHG-UHFFFAOYSA-N CC1=C(C=CC(=C1)CCONC(=O)C=C(C(=O)O)O)F Chemical compound CC1=C(C=CC(=C1)CCONC(=O)C=C(C(=O)O)O)F SYOUNFPGFYUNHG-UHFFFAOYSA-N 0.000 claims 1
- 108010002459 HIV Integrase Proteins 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YOYZQYPQBXGYGP-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(F)=C1 YOYZQYPQBXGYGP-UHFFFAOYSA-N 0.000 claims 1
- VUPLYDPQETXFOM-UHFFFAOYSA-N n-[(3-bromo-4-fluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(Br)=C1 VUPLYDPQETXFOM-UHFFFAOYSA-N 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
- C07C207/04—Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
- C07C255/64—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (19)
1. Соединение формулы I
в которой R1 представляет собой
-арил,
-C1-С6алкиларил,
-C1-С6алкил-S(O)n-арил,
-C1-C5алкил-O-арил; или
когда R1 является незамещенным или независимо замещенным 1-3 R3;
каждый R3 независимо выбирают из
-Н,
-галогена,
-CN.
-C1-C6алкила,
-С3-С6циклоалкила,
-OR4,
-C1-С10алкил-O-R4,
-CO2R5,
-С1-С10алкил-СО2R5,
-NC(R6)(R7),
-С1-С10алкил-N(R6)(R7),
-CON(R6)(R7),
-C1-С10алкил-CON(R6)(R7)
-S(O)nR8,
-C1-С10алкил-S(O)nR8,
-S(O)nN(R9)(R10),
-C1-С10алкил-S(O)nN(R9)(R10),
-арила,
-O-арила,
-гетероарила,
-O-гетероарила,
-C1-С6алкиларила,
-C1-С6алкилгетероарила,
-С(O)-гетероциклического радикала,
-C1-С10алкил-С(O)-гетероциклического радикала или
-C1-С6галогеналкила;
R2 представляет собой
-Н,
-С1-С10алкил,
-С3-С6циклоалкил,
-C1-C10галогеналкил,
-арил,
-гетероарил,
-C1-С6алкиларил,
-C1-C5алкил-O-арил,
-C1-С6алкилгетероарил,
-C1-C5алкил-O-гетероарил,
-C1-С10алкил-OR4,
-C1-С10алкил-CO2R5,
-С1-С10алкил-N(R6)(R7),
-C1-С10алкил-CON(R6)(R7),
-C1-С10алкил-S(O)nR8,
-C1-С10алкил-S(O)nN(R9)(R10) или
-C1-С10алкил-С(O)-гетероциклический радикал;
каждый R4 независимо выбран из
-Н,
-C1-С6алкила,
-С3-С6циклоалкила,
-C1-C9алкил-CO2R5,
-C1-C9алкил-N(R6)(R7),
-C1-C9алкил-CON(R6)(R7),
-C1-C9алкил-S(O)nR8 или
-C1-C9алкил-S(O)nN(R9)(R10);
каждый R5 независимо выбран из
-Н,
-C1-С6алкила,
-С3-С6циклоалкила или
-C1-С6алкиларила;
каждый R6 независимо выбран из
-Н,
-C1-С6алкила,
-арила,
-гетероарила,
-C1-С6алкиларила,
-С1-С6алкилгетероарила,
-С(O)-С1-С6алкила,
-С(O)-арила,
-C(O)-C1-C6алкиларила,
-С(O)-гетероарила,
-С(O)-С1-С6алкилгетероарила,
-C(NH)NH2,
-S(0)n-R8 или
-С1-С5алкил-CO2R5;
каждый R7 независимо выбран из
-Н,
-C1-С6алкила,
-арила или
-гетероарила;
каждый R8 независимо выбран из
-C1-С6алкила,
-арила или
-гетероарила;
каждый R9 независимо выбран из
-Н,
-C1-С6алкила,
-C1-С6алкиларила,
-C1-С6алкилгетероарила,
-С(O)-С1-С6алкила,
-С(O)-арила,
-C(O)-C1-C6алкиларила,
-С(O)-гетероарила,
-C(O)-C1-C6алкилгетероарила,
-арила или
-гетероарила;
каждый R10 независимо выбран из
-Н,
-C1-С6алкила,
-C1-С6алкиларила,
-C1-С6алкилгетероарила,
-арила или
-гетероарила;
R11 представляет собой
-Н,
-арил,
-гетероарил,
-C1-С6алкилгетероарил,
-C1-С6алкил,
-C1-С6алкиларил,
-C1-С6алкил-СО2R5 или
-C1-С6алкил-N(R6)(R7);
R12 представляет собой
-Н,
-C1-С6алкил,
-арил или
-гетероарил;
R13 представляет собой
-Н,
-C1-С6алкил,
-арил
или -гетероарил;
и R12 и R13, взятые вместе могут образовывать циклический алкильный кеталь;
В1 выбран из группы, состоящей из
n имеет значение 0, 1 или 2;
или его фармацевтически приемлемую соль или сольват.
2. Соединение по п.1, где
R1 представляет собой
- фенил или -C1-С2алкилфенил, где фенил является незамещенным или независимо замещенным 1-3 R3;
каждый R3 независимо выбран из
-Н,
-галогена,
-CN,
-C1-С6алкила,
-OC1-С6алкила,
-CO2R5,
-N(R6)(R7),
-CON(R6)(R7),
-трифторметила;
R2 представляет собой
-C1-С6 алкил,
-СН2-фенил,
-CH2-CO2R5,
-C1-C2-алкил-N(R6)(R7),
-CH2-CON(R6)(R7),
-СН2-С(О)-гетероциклический радикал;
R11 представляет собой R5;
R12 и R13 представляют собой C1-С6алкил или могут совместно образовывать циклический алкильный кеталь;
В1 выбран из группы, состоящей из
4. Соединение по п.3, выбранное из группы, состоящей из:
3-[(4-Фторбензил)-метоксикарбамоил]-2-гидроксиакриловой кислоты;
3-[(3,4-Дифторбензил)-метоксикарбамоил]-2-гидроксиакриловой кислоты;
3-[(3-Бром-4-фторбензил)-метоксикарбамоил]-2-гидроксиакриловой кислоты;
3-[(3-Циано-4-фторбензил)-метоксикарбамоил]-2-гидроксиакриловой кислоты;
3-[(4-Фтор-3-метилбензил)-метоксикарбамоил]-2-гидроксиакриловой кислоты;
3-[Этокси-(4-фторбензил)-карбамоил]-2-гидроксиакриловой кислоты.
12. Соединение по п.1, где
R1 представляет собой
где R14, R14' и R14" каждый неависимо выбран из циано, водорода или галогена;
R2 представляет собой C1-C2алкил или -CH2C(O)N(CH3)2;
и В1 представляет собой
в которой R12 и R13 каждый неависимо является C1-С6 алкилом или взятые вместе образуют циклический алкильный кеталь.
13. Соединение по п.12, где R12 и R13 представляют собой метил.
14. Соединение по п.13, выбранное из группы, состоящей из:
2-(2,2-Диметил-5-оксо-[1,3]диоксолан-4-илиден)-N-(4-фторбензил)-N-метоксиацетамида;
N-(3,4-Дифторбензил)-2-(2,2-диметил-5-оксо-[1,3]диоксолан-4-илиден)-N-метоксиацетамида;
N-(3-Бром-4-фторбензил)-2-(2,2-диметил-5-оксо-[1,3]диоксолан-4-илиден)-N-метоксиацетамида;
N-(3-Циано-4-фторбензил)-2-(2,2-диметил-5-оксо-[1,3]диохолан-4-илиден)-N-метоксиацетамида;
2-(2,2-Диметил-5-оксо-[1,3]диоксолан-4-илиден)-N-(4-фтор-3-метилбензил)-N-метоксиацетамида;
2-(2,2-Диметил-5-оксо-[1,3]диоксолан-4-илиден)-N-этокси-N-(4-фторбензил)-ацетамида.
16. Композиция, пригодная для лечения ВИЧ инфекций, содержащая терапевтическое количество соединения по п.1 и фармацевтически приемлемый носитель.
17. Фармацевтическая композиция по п.16, дополнительно содержащая терапевтически эффективное количество одного или более других агентов для лечения ВИЧ, выбранных из
(a) ингибитора ВИЧ протеазы,
(b) нуклеозидного ингибитора реверсивной транскриптазы,
(c) ненуклеозидного ингибитора реверсивной транскриптазы,
(d) ВИЧ-входящего ингибитора,
(e) иммуномодулятора
или их комбинаций.
18. Способ ингибирования ВИЧ интегразы, включающий введение млекопитающим, нуждающимся в таком лечении, терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли или сольвата.
19. Способ лечения ВИЧ инфекции у пациента, нуждающегося в нем, включающий введение такому пациенту терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли или сольвата.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33967401P | 2001-12-12 | 2001-12-12 | |
US60/339,674 | 2001-12-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004119963A true RU2004119963A (ru) | 2006-01-10 |
RU2284315C2 RU2284315C2 (ru) | 2006-09-27 |
Family
ID=23330105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004119963/04A RU2284315C2 (ru) | 2001-12-12 | 2002-12-06 | Ингибиторы вич-интегразы и содержащие их фармацевтические композиции |
Country Status (24)
Country | Link |
---|---|
US (1) | US6777440B2 (ru) |
EP (1) | EP1467695A2 (ru) |
JP (1) | JP2005515206A (ru) |
KR (1) | KR20040065251A (ru) |
CN (1) | CN1617849A (ru) |
AR (1) | AR037770A1 (ru) |
AU (1) | AU2002366604A1 (ru) |
BR (1) | BR0214842A (ru) |
CA (1) | CA2469592C (ru) |
CO (1) | CO5590909A2 (ru) |
HR (1) | HRP20040534A2 (ru) |
HU (1) | HUP0402675A2 (ru) |
IL (1) | IL162325A0 (ru) |
IS (1) | IS7305A (ru) |
MX (1) | MXPA04005623A (ru) |
NO (1) | NO20042916L (ru) |
NZ (1) | NZ533413A (ru) |
PE (1) | PE20030763A1 (ru) |
PL (1) | PL370664A1 (ru) |
RU (1) | RU2284315C2 (ru) |
TW (1) | TWI252757B (ru) |
UY (1) | UY27577A1 (ru) |
WO (1) | WO2003049690A2 (ru) |
ZA (1) | ZA200404628B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169932B2 (en) | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
US7094909B2 (en) | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
PA8586801A1 (es) | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
BRPI0407052A (pt) | 2003-01-27 | 2006-01-17 | Pfizer | Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização |
US6890942B2 (en) * | 2003-05-16 | 2005-05-10 | Bristol-Myers Squibb Company | Acyl sulfonamides as inhibitors of HIV integrase |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
EP1756103A2 (en) | 2004-04-26 | 2007-02-28 | Pfizer, Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
CA2563761C (en) | 2004-04-26 | 2009-12-29 | Pfizer Inc. | Inhibitors of the hiv integrase enzyme |
US7507838B2 (en) * | 2004-09-01 | 2009-03-24 | Bristol-Myers Squibb Company | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones |
US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規FabKおよびFabI/K阻害剤 |
WO2008004100A2 (en) | 2006-07-05 | 2008-01-10 | Pfizer Products Inc. | Therapeutic compounds |
CA2744509C (en) * | 2008-12-05 | 2013-10-22 | Syngenta Participations Ag | Novel pyrazole-4-n-alkoxycarboxamides as microbiocides |
WO2011076765A1 (en) | 2009-12-23 | 2011-06-30 | Katholieke Universiteit Leuven | Novel antiviral compounds |
US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
WO2012065963A2 (en) | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
IN2014DN09934A (ru) * | 2012-04-26 | 2015-08-14 | Bayer Cropscience Ag |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR029304A1 (es) * | 1998-06-26 | 2003-06-25 | Daiichi Seiyaku Co | DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS |
-
2002
- 2002-12-06 KR KR10-2004-7009018A patent/KR20040065251A/ko not_active Application Discontinuation
- 2002-12-06 TW TW091135471A patent/TWI252757B/zh not_active IP Right Cessation
- 2002-12-06 MX MXPA04005623A patent/MXPA04005623A/es unknown
- 2002-12-06 AU AU2002366604A patent/AU2002366604A1/en not_active Abandoned
- 2002-12-06 WO PCT/US2002/039092 patent/WO2003049690A2/en not_active Application Discontinuation
- 2002-12-06 IL IL16232502A patent/IL162325A0/xx unknown
- 2002-12-06 CN CNA028279700A patent/CN1617849A/zh active Pending
- 2002-12-06 CA CA002469592A patent/CA2469592C/en not_active Expired - Fee Related
- 2002-12-06 JP JP2003550741A patent/JP2005515206A/ja not_active Withdrawn
- 2002-12-06 EP EP02804741A patent/EP1467695A2/en not_active Withdrawn
- 2002-12-06 BR BR0214842-0A patent/BR0214842A/pt not_active Withdrawn
- 2002-12-06 US US10/313,058 patent/US6777440B2/en not_active Expired - Lifetime
- 2002-12-06 HU HU0402675A patent/HUP0402675A2/hu unknown
- 2002-12-06 RU RU2004119963/04A patent/RU2284315C2/ru not_active IP Right Cessation
- 2002-12-06 PL PL02370664A patent/PL370664A1/xx not_active Application Discontinuation
- 2002-12-06 NZ NZ533413A patent/NZ533413A/en unknown
- 2002-12-10 AR ARP020104777A patent/AR037770A1/es not_active Application Discontinuation
- 2002-12-11 UY UY27577A patent/UY27577A1/es not_active Application Discontinuation
- 2002-12-12 PE PE2002001198A patent/PE20030763A1/es not_active Application Discontinuation
-
2004
- 2004-06-09 CO CO04054295A patent/CO5590909A2/es not_active Application Discontinuation
- 2004-06-10 IS IS7305A patent/IS7305A/is unknown
- 2004-06-10 ZA ZA200404628A patent/ZA200404628B/en unknown
- 2004-06-11 HR HR20040534A patent/HRP20040534A2/hr not_active Application Discontinuation
- 2004-07-09 NO NO20042916A patent/NO20042916L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA04005623A (es) | 2004-12-06 |
PL370664A1 (en) | 2005-05-30 |
US6777440B2 (en) | 2004-08-17 |
TWI252757B (en) | 2006-04-11 |
PE20030763A1 (es) | 2003-09-13 |
TW200301105A (en) | 2003-07-01 |
KR20040065251A (ko) | 2004-07-21 |
WO2003049690A3 (en) | 2004-01-22 |
HUP0402675A2 (hu) | 2005-03-29 |
CO5590909A2 (es) | 2005-12-30 |
RU2284315C2 (ru) | 2006-09-27 |
IS7305A (is) | 2004-06-10 |
UY27577A1 (es) | 2003-07-31 |
AR037770A1 (es) | 2004-12-01 |
NZ533413A (en) | 2006-09-29 |
CA2469592A1 (en) | 2003-06-19 |
NO20042916L (no) | 2004-09-10 |
IL162325A0 (en) | 2005-11-20 |
HRP20040534A2 (en) | 2005-04-30 |
WO2003049690A2 (en) | 2003-06-19 |
EP1467695A2 (en) | 2004-10-20 |
CN1617849A (zh) | 2005-05-18 |
BR0214842A (pt) | 2005-01-11 |
CA2469592C (en) | 2005-08-23 |
US20030176495A1 (en) | 2003-09-18 |
AU2002366604A1 (en) | 2003-06-23 |
JP2005515206A (ja) | 2005-05-26 |
ZA200404628B (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004119963A (ru) | Ингибиторы вич интегразы | |
RU2002121646A (ru) | 1,3-дизамещенные пирролидины в качестве антагонистов альфа-2-адренорецепторов | |
RU2481346C2 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
JP2004537564A5 (ru) | ||
RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
RU2008128452A (ru) | Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения | |
RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
JP2004502761A5 (ru) | ||
RU2000128036A (ru) | Амидиновые соединения | |
RU2003116648A (ru) | Замещенные имидазопиридины | |
RU2004135066A (ru) | Ингибиторы деацетилазы гистонов | |
RU2002129564A (ru) | Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с | |
CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
JP2012528166A5 (ru) | ||
JP2010510233A5 (ru) | ||
RU2001132570A (ru) | Мочевинозамещенные имидазохинолины | |
RU2004125279A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита c | |
RU2007140244A (ru) | Произвдное соединение пропан-1,3-диона или его соль | |
JP2004518723A5 (ru) | ||
RU2003110577A (ru) | Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами | |
JP2007515405A5 (ru) | ||
RU2008107727A (ru) | Макроциклические ингибиторы вируса гепатита с | |
JP2006513202A5 (ru) | ||
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20061207 |